Advertisement

Das Bronchialkarzinom

  • K. W. Brunner
  • G. A. Nagel

Zusammenfassung

Das Bronchialkarzinom ist in allen westlichen Ländern beim Mann weitaus die häufigste zum Tode führende Neoplasie. Im Jahre 1972 entfielen in den USA von 187.000 Krebstodesfällen beim Mann 30% auf das Lungenkarzinom; beim weiblichen Geschlecht waren es immerhin 8%. Die wichtigsten Probleme beim Bronchialkarzinom sind seine von Jahr zu Jahr weiterhin steigende Häufigkeit und die geringen Heilungschancen und die in den meisten Fällen kurzfristig schlechte Prognose.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. 213.
    ALBERTO, P.: Remission rates, survival and prognostic factors in combination chemotherapy for bronchogenic carcinoma. Cancer Chemother. Rep. Part 3, 4, 199 (1973).Google Scholar
  2. 214.
    BERGSAGEL, D.E., ROBERTSON, G.L., HASSELBACK, R.: Effects of cyclophosphamide on advanced lung cancer and the hematologic toxicity of large intermittent intravenous doses. Canad. med. Ass. J. 98, 532 (1968).PubMedGoogle Scholar
  3. 215.
    BRUNNER, K.W.: Die nicht-chirurgische Behandlung des Bronchuskarzinoms. Bern-Stuttgart-Wien: Huber 1973.Google Scholar
  4. 216.
    BRUNNER, K.W., MARTHALER, Th., MüLLER, W.: Effects of long-term adjuvant chemotherapy with cyclophosphamide for radically resected bronchogenic carcinoma. Cancer Chemother. Rep. Part 3, 4, 125 (1973).Google Scholar
  5. 217.
    CUTLER, S.J.: End results in cancer. Report No.3. US Department of Health, Education and Welfare, Public Health Service. Washington: US Government Printing Office 1968.Google Scholar
  6. 218.
    DEELEY, T.J.: Modern radiotherapy. Carcinoma of the bronchus. New York: Appleton-Century-Crofts 1971.Google Scholar
  7. 219.
    HANSEN, H.H., MUGGIA, F.M., ANDREWS, R., SELAWRY, O.S.: Intensive combined chemotherapy and radiotherapy in patients with non-resectable bronchogenic carcinoma. Cancer (Philad.) 30, 315 (1972).CrossRefGoogle Scholar
  8. 220.
    HIGGINS, G.: The use of chemotherapy as an adjuvant to surgery for bronchogenic carcinoma. Cancer (Philad.) 30, 1383 (1972).CrossRefGoogle Scholar
  9. 220a.
    LIVINGSTON, R.B., BODEY, G.P., GOTTLIEB, J.A., BURGESS, M.A.: Cytoxan, Oncovin, Methyl-CCNU and Bleomycin (COMB) in lung cancer and other solid tumors. Cancer Chemother. Rep. Part 1, 57, 105 (1973).Google Scholar
  10. 221.
    ROSWIT, B., PATNO, M.E., RAPP, R., VEINBERG, A., FEDER, B., STUHLBARG, J., REID, C.B.: The survival of patients with inoperable lung cancer: A large scale randomized study of radiation therapy versus placebo. Radiology 90, 688 (1968).PubMedGoogle Scholar
  11. 222.
    SELAWRY, O.S.: Monochemotherapy of bronchogenic carcinoma. With special reference to cell types. Cancer Chemother. Rep. Part 3, 4, 177 (1973).Google Scholar
  12. 223.
    SELAWRY, O.S., HANSEN, H.H.: Lung cancer. In: HOLLAND, J.F., FREI, E. III (Eds.): Cancer medicine, S.1473. Philadelphia: Lea & Febiger 1973.Google Scholar
  13. 224.
    SELAWRY, O.S., STRAUS, M.J. (Eds.): Lung cancer. Sem. Oncol, 1, 161 (1974).Google Scholar
  14. 225.
    SHIELDS, T.W.: Status report of adjuvant cancer chemotherapy trials in the treatment of bronchial carcinoma. Cancer Chemother. Rep. Part 3, 4, 119 (1973).Google Scholar
  15. 226.
    SLACK, N.H.: Bronchogenic carcinoma. Nitrogen mustard as a surgical adjuvant and factors influencing survival. Cancer (Philad.) 25, 987 (1970).CrossRefGoogle Scholar
  16. S. auch: Kapitel 8: 57Google Scholar
  17. Kapitel 27: 305Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1976

Authors and Affiliations

  • K. W. Brunner
    • 1
  • G. A. Nagel
    • 2
  1. 1.InselspitalBernSchweiz
  2. 2.Kantonsspital Basel, Dept. für Innere Medizin1. Medizinische Universitäts-Klinik, Abt. für OnkologieBaselSchweiz

Personalised recommendations